Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07456774
Enrolling by invitation Observational

A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China

NCT07456774 · tracked via the Priya Life Science China tracker
Sponsor
Novo Nordisk A/S
Phase
Observational
Started
2026-02-13
Last updated
2026-05-20

Condition(s) studied

Type 2 Diabetes

Study summary

The study is testing the incidence of MACE and incidence of renal events between Ozempic® users and users with other anti-diabetic medications in T2D patients. This is a retrospective study, and participants had received Ozempic or any other anti-diabetic medications.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Participants had at least one prescription for Ozempic® or other interested anti-diabetic medications during the index identification period. * Participants had at least one diagnosis of T2D, and had at least one of the three following T2D clinical evidence any time before or on the index date * Participants had at least 1 all-cause visit record any time after 6 months post-index date. * At least 18 years old at the index date. Exclusion Criteria: * Patients who have used any same anti-diabetic medications as the index treatment within 6 months before index date (e.g., patient prescribed with any Ozempic® during baseline will be excluded if the index drug is a Ozempic®) * Patients with any diagnosis record of type 1 diabetes or gestational diabetes during whole study period. * Patients who were pregnant during the whole study period. * Patients who participated in any clinical trials during the whole study period. * Patients who were diagnosed with medullary thyroid carcinoma or multiple endocrine neoplasia type II (MEN2) during the whole study period.

Primary outcome measure(s)

  • Time to 3P major adverse cardiovascular events — From index date to the first composite 3P MACE (stroke, myocardial infarction, all-cause death) event or censoring event (up to 36 months)
    Measured in days.
  • Time to 5P MACE — From index date to the first composite 5P MACE (stroke, myocardial infarction, all-cause death, heart failure hospitalization, coronary revascularization) event or censoring event (up to 36 months)
    Measured in days.
  • Time to stroke — From index date to the first stroke event or censoring event (up to 36 months)
    Measured in days.
  • Time to myocardial infarction (MI) — From index date to the first MI event or censoring event (up to 36 months)
    Measured in days.
  • Time to heart failure (HF) — From index date to the first HF event or censoring event (up to 36 months)
    Measured in days.
  • Time to composite renal event — From index date to first composite renal (kidney failure: dialysis/transplantation/eGFR <15, ≥50% eGFR reduction from baseline, or kidney-related/cardiovascular death) or censoring event (up to 36 months)
    Measured in days.
  • Time to renal disease-related hospitalization — From index date to the first renal disease-related hospitalization or censoring event (up to 36 months)
    Measured in days.
  • Incidence rate of 3P MACE — From index date to the first composite 3P MACE (stroke, myocardial infarction, all-cause death) event or censoring event (up to 36 months)
    Measured in Percentage, per 1000 patient year.
  • Incidence rate of 5P MACE — From index date to the first composite 5P MACE (stroke, myocardial infarction, all-cause death, heart failure hospitalization, coronary revascularization) event or censoring event (up to 36 months)
    Measured in Percentage, per 1000 patient year.
  • Incidence rate of stroke — From index date to the first stroke event or censoring event (up to 36 months)
    Measured in Percentage, per 1000 patient year.
  • Incidence rate of myocardial infarction — From index date to the first MI event or censoring event (up to 36 months)
    Measured in Percentage, per 1000 patient year.
  • Incidence rate of heart failure — From index date to the first HF event or censoring event (up to 36 months)
    Measured in Percentage, per 1000 patient year.
  • Incidence rate of composite renal event — From index date to first composite renal (kidney failure: dialysis/transplantation/eGFR <15, ≥50% eGFR reduction from baseline, or kidney-related/cardiovascular death) or censoring event (up to 36 months)
    Measured in Percentage, per 1000 patient year.
  • Incidence rate of renal disease-related hospitalization — From index date to the first renal disease-related hospitalization or censoring event (up to 36 months)
    Measured in Percentage, per 1000 patient year.

Trial sites (1)

FacilityCityRegionStatus
NIS- Tianjin Medical University Chu Hsien-I Memorial Hospital-Department of Endocrinology Tianjin Tianjin Municipality

More Novo Nordisk A/S trials in China

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity Recruiting
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea Recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity Starting soon
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow Active, not recruiting
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) Active, not recruiting

Other trials for the same condition

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes Active, not recruiting
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes Starting soon
LCMD for Type 2 Diabetes Remission: Evaluation of Effectiveness and Exploration of Individual Differences Starting soon
Efficacy Heterogeneity of Lactobacillus Paracasei LC19 on Type 2 Diabetes Starting soon
Characteristics of Papez Loop Neural Network in T2DM （Type 2 Diabetes Mellitus） Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07456774 on ClinicalTrials.gov ↗ ← All trials in China